Bristol-Myers Squibb Company plans to lay off 224 pharmaceutical sales representatives, 22 area and sales managers, and 14 people supporting scientific pharmaceutical information and the headquarters in Rome. The company cited several problems behind its decision to cut staff: the Italian unit's financial situation of the past two years, the specific actions taken by the Italian government and regulatory bodies concerning the limits and timing of inserting new drugs in the national pharmaceutical lists, plus healthcare spending cuts. Another factor for cutting staff is the impact of the review on global level of some commercial cooperation accords.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.75 USD | -0.90% |
|
+1.72% | -20.58% |
Jul. 11 | Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $50 From $54, Maintains Neutral Rating | MT |
Jul. 10 | Barclays Adjusts Price Target on Bristol-Myers Squibb to $41 From $43 | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.58% | 83.35B | |
+60.25% | 846B | |
+38.56% | 628B | |
-4.49% | 360B | |
+18.30% | 322B | |
+9.64% | 297B | |
+14.15% | 240B | |
+3.11% | 224B | |
+16.98% | 223B | |
+12.87% | 173B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Bristol-Myers Squibb Company Plans to Cut 260 Staff in Italy